| Description | The antibody UT28K is a human mAb specific for SARS-CoV-2 Spike S1 protein. It showed efficacy in neutralizing SARS-CoV-2 in an in vitro assay and in vivo prophylactic treatment, and the reactivity to the Omicron strain was reduced. The antibody and SARS-CoV-2 RBD protein interactions were mainly chain-dominated antigen-antibody interactions. |
| Clonality | Monoclonal |
| Host Species | Human |
| Target Species | SARS-CoV-2 |
| Epitope | Receptor-binding domain (RBD) |
| Isotype | IgG1 |
| Expression Species | HEK293F or CHO cell line |
| Conjugation | Unconjugated |
| Purity | >95% |
| Endotoxin | <1 EU/mg |
| Form | Liquid |
| Purification | Protein A purified |
| Sterility | 0.2 μM filtered |
| Formulation | PBS, pH 7.4 |
| Preservation | No preservatives |
| Stabilizer | No stabilizers |
| Storage | Store at 4°C within one or two weeks. Store at -20°C for long term. Avoid repeated freeze/thaw cycles. Refer to the COA file for specifics. |
| Application | ELISA, Neut |
| Application Notes | To analyze the antibody binding to spike and RBD protein, we coated the wells of 96-well MaxiSorp plates with 50 μl of 1 μg/ml protein in PBS and subsequently blocked nonspecific protein binding with 3% BSA in PBS. After washing, we added antibodies to the plates and incubated them at RT for 1 h. After washing, we detected the antibodies that had bound to protein using horseradish peroxidase-conjugated anti-human IgG-Fc specific antibodies and TMB substrate. Optical absorbance at 450 nm was measured using the OPTIMA plate reader. |
| ELISA | Enzyme-Linked Immunosorbent Assay Protocol |
| WB | Western Blot Protocol |
| FC | Western Blot Protocol |
| Target | SARS-CoV-2 |
| Alternative Name | Severe acute respiratory syndrome coronavirus 2 |
| Research Area | Coronavirus Disease 2019 |
| Related Disease | Coronavirus Disease 2019 |
